These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Pälvimäki EP; Roth BL; Majasuo H; Laakso A; Kuoppamäki M; Syvälahti E; Hietala J Psychopharmacology (Berl); 1996 Aug; 126(3):234-40. PubMed ID: 8876023 [TBL] [Abstract][Full Text] [Related]
44. Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. Liu X; Zhang J; Sun D; Fan Y; Zhou H; Fu B Clin Interv Aging; 2014; 9():411-8. PubMed ID: 24648723 [TBL] [Abstract][Full Text] [Related]
45. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Illi A; Setälä-Soikkeli E; Viikki M; Poutanen O; Huhtala H; Mononen N; Lehtimäki T; Leinonen E; Kampman O Neuroreport; 2009 Aug; 20(12):1125-8. PubMed ID: 19590397 [TBL] [Abstract][Full Text] [Related]
46. Mean platelet volume and platelet distribution width in vascular dementia and Alzheimer's disease. Liang QC; Jin D; Li Y; Wang RT Platelets; 2014; 25(6):433-8. PubMed ID: 24175580 [TBL] [Abstract][Full Text] [Related]
47. Loss of Serotonin Transporter Function Alters ADP-mediated Glycoprotein αIIbβ3 Activation through Dysregulation of the 5-HT2A Receptor. Oliver KH; Duvernay MT; Hamm HE; Carneiro AM J Biol Chem; 2016 Sep; 291(38):20210-9. PubMed ID: 27422820 [TBL] [Abstract][Full Text] [Related]
48. Whole Blood Serotonin Levels and Platelet 5-HT Aaron E; Montgomery A; Ren X; Guter S; Anderson G; Carneiro AMD; Jacob S; Mosconi M; Pandey GN; Cook E; Veenstra-VanderWeele J J Autism Dev Disord; 2019 Jun; 49(6):2417-2425. PubMed ID: 30927179 [TBL] [Abstract][Full Text] [Related]
50. Platelet 5-HT2A receptor subresponsivity and lethality of attempted suicide in depressed in-patients. Malone KM; Ellis SP; Currier D; John Mann J Int J Neuropsychopharmacol; 2007 Jun; 10(3):335-43. PubMed ID: 16893479 [TBL] [Abstract][Full Text] [Related]
51. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. Amitai M; Kronenberg S; Carmel M; Michaelovsky E; Frisch A; Brent D; Apter A; Chen A; Weizman A; Fennig S J Neural Transm (Vienna); 2016 Nov; 123(11):1347-1354. PubMed ID: 27324805 [TBL] [Abstract][Full Text] [Related]
52. Lack of association between suicidal ideation and enhanced platelet 5-HT2A receptor-mediated calcium mobilization in cancer patients with depression. Uchitomi Y; Kugaya A; Akechi T; Nakano T; Inagaki M; Matsuoka Y; Kagaya A; Yamawaki S Biol Psychiatry; 2002 Dec; 52(12):1159-65. PubMed ID: 12488061 [TBL] [Abstract][Full Text] [Related]
53. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Choi MJ; Kang RH; Ham BJ; Jeong HY; Lee MS Neuropsychobiology; 2005; 52(3):155-62. PubMed ID: 16127283 [TBL] [Abstract][Full Text] [Related]
54. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder. Corregiari FM; Bernik M; Cordeiro Q; Vallada H Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758 [TBL] [Abstract][Full Text] [Related]
55. Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study. Van Holten TC; Roest M; Riphagen J; Jansen C; Naarding P; Adriaansen HJ; De Groot PG; Remijn JA J Thromb Haemost; 2012 Jun; 10(6):1177-9. PubMed ID: 22429872 [No Abstract] [Full Text] [Related]
56. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. van Zyl LT; Lespérance F; Frasure-Smith N; Malinin AI; Atar D; Laliberté MA; Serebruany VL J Thromb Thrombolysis; 2009 Jan; 27(1):48-56. PubMed ID: 18188512 [TBL] [Abstract][Full Text] [Related]
57. Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer's-like disease in mice. von Linstow CU; Waider J; Grebing M; Metaxas A; Lesch KP; Finsen B Alzheimers Res Ther; 2017 Sep; 9(1):74. PubMed ID: 28899417 [TBL] [Abstract][Full Text] [Related]
58. Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Millan MJ; Veiga S; Girardon S; Brocco M Psychopharmacology (Berl); 2003 Aug; 168(4):397-409. PubMed ID: 12721776 [TBL] [Abstract][Full Text] [Related]
59. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. Siddique H; Hynan LS; Weiner MF J Clin Psychiatry; 2009 Jun; 70(6):915-8. PubMed ID: 19422762 [TBL] [Abstract][Full Text] [Related]
60. Advancements in the treatment of agitation in Alzheimer's disease. Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]